{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "CRL",
  "name": "Charles River Laboratories International, Inc.",
  "url": "https://orbyd.app/dossiers/CRL/",
  "json_url": "https://orbyd.app/dossiers/CRL.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Elliott-driven turnaround at a beaten-down CRO: a ~$295M cost program plus 120–150bps margin expansion is re-rating the stock even with organic revenue still negative (-1.5% Q1), while Q1 proposals up high-single-digits YoY hint DSA bookings are bottoming. The 2026-08-05 Q2 print is the binary gate — at ~14x forward EPS this is a probe-not-chase turnaround base, not an accelerating momentum leg.",
  "invalidation_trigger": "A weekly close below $140 loses the 2026 post-activist recovery base and the lowest analyst floor; a secondary break is the 2026-08-05 Q2 print delivering an organic-revenue guide cut, DSA book-to-bill under 1.0, or proposals rolling over.",
  "catalyst_date": "2026-08-05",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Q2 2026 earnings 2026-08-05 before open (9:00 a.m. ET call) — binary print ~7-8 trading days out; avoid fresh size into it.",
    "Recovery is cost/margin-driven, not demand-driven: organic revenue still negative (-1.5% Q1 2026, FY guide -0.5% to -1.5%); reported top line -5.5% to -4.0% on ~$200M+ divestiture drag.",
    "Leading indicator to watch: Q1 2026 proposals +high-single-digits YoY in both biopharma and biotech — needs to convert to DSA bookings on 2026-08-05.",
    "Analyst-target divergence: MS Overweight $260 (2026-07-09) and Mizuho Neutral $230 (2026-07-13) sit above a still-Hold consensus (~$177 avg, range $140-$210) — outliers, not base case.",
    "Theme tag corrected from 'precision-biotech-therapeutics' (mislabel — CRL is a CRO, not a therapeutics developer) to CRO/funding-recovery/activist frame.",
    "Watch for a 2026 Investor Day date (TBD) — structural re-rate catalyst to reset long-term targets."
  ],
  "body_markdown": "## Current Thesis\nCharles River is the arms dealer to drug development — research models, discovery and safety assessment (DSA), and manufacturing solutions sold into pharma and biotech. The tape from 2023–2025 priced it as a structural loser: biotech funding winter gutted preclinical demand, NHP (non-human primate) cost inflation and the DOJ Cambodia-import overhang hit the profit engine, and the stock lost more than half its value. The active narrative now is not growth — it is an Elliott-driven turnaround. Since the May 2025 cooperation agreement, the board was refreshed, a Strategic Planning and Capital Allocation Committee stood up, roughly $225M of annualized cost savings plus ~$70M of incremental efficiencies were committed for 2026, and non-core lines (~7% of 2025 revenue) are being divested. The re-rate is being paid for by margins, not demand: FY2026 guidance (reaffirmed 2026-05-07) embeds 120–150 bps of margin expansion, H2-weighted, against organic revenue of -0.5% to -1.5%. What makes it interesting NOW is a leading-indicator inflection — Q1 2026 proposals rose high-single-digits YoY in both biopharma and biotech — and a sell-side that is starting to warm (MS Overweight, Mizuho PT bump) ahead of a still-Hold consensus. The catch: the whole thing runs into a binary Q2 print on 2026-08-05.\n\n## Bull Case\n- **Proposal inflection precedes bookings.** Q1 2026 (reported 2026-05-07) showed proposals up high-single-digits YoY across both global biopharma and biotech — the leading indicator that historically front-runs DSA bookings by one to two quarters. If Q2 confirms bookings following, the demand-recovery leg becomes real rather than hoped-for.\n- **Self-help EPS leverage.** The ~$225M annualized cost program plus ~$70M incremental efficiencies are fully realized in 2026, and guidance carries 120–150 bps of margin expansion weighted to H2. That produces EPS growth on flat-to-negative organic revenue — the guide holds non-GAAP EPS at $10.80–$11.30.\n- **Activist catalyst path.** Elliott's May 2025 cooperation agreement, the four new directors, the strategic review, and a 2026 Investor Day (date TBD) to reset long-term targets give a scripted sequence of re-rate events. The 2025-11-05 update and the cell-therapy CDMO closure show the committee is actually cutting, not just studying.\n- **Valuation skew.** At ~$157 (mid-July 2026) on ~$11 forward EPS, the stock trades near 14x — well below its historical 20x+ multiple for a franchise CRO. The lowest analyst target sits at $140 (~-11%) against a Street-high $260 (Morgan Stanley, 2026-07-09), an asymmetric payoff if the turnaround converts.\n- **Sell-side beginning to move.** Two PT raises in a week (Morgan Stanley Overweight to $260 on 2026-07-09; Mizuho Neutral to $230 on 2026-07-13) against a consensus still rated Hold — the \"before the Street catches up\" window this playbook targets.\n\n## Bear Case\n- **The recovery is cost-driven, not demand-driven.** Organic revenue fell 1.5% in Q1 2026 and FY guidance is -0.5% to -1.5%. DSA — the profit engine — is still contracting organically. Margin math re-rates a shrinking business only until the cuts are lapped.\n- **The top line optically shrinks all year.** Divestitures cut reported revenue by more than $200M in 2026, dragging reported growth to -5.5% to -4.0%. Headline prints stay red even if the underlying stabilizes.\n- **Margin pressure is not fully cleared.** Q1 margins absorbed NHP cost inflation and CEO-transition stock compensation; the NHP supply and regulatory overhang from the DOJ Cambodia matter has not been fully retired.\n- **Fragile end-demand.** Management flagged that small- and mid-biotech activity \"fluctuated\" by region and business line in Q1. That cohort is the swing factor, and it moves with venture funding, which is not durably back.\n- **Consensus is not convinced.** The stock is rated Hold (roughly 9 hold / 6 buy / 1 sell) with an aggregate target in the high $170s; the $230–$260 prints are the tail, not the base case. If proposals fail to convert to bookings on 2026-08-05, the setup is a value trap at 14x.\n\n## Setup & Price Structure\nPrice sits near $157 (mid-July 2026), mid-range between the lowest analyst target of $140 and the Street-high $260, and well recovered off the 2024–2025 lows. This is a turnaround base consolidating, not an accelerating breakout: organic revenue is still negative and there is no parabolic volume leg to ride. Overhead supply clusters into the high $170s / $180 (the average-target zone); the floor of interest is the post-activist recovery shelf near $140, which doubles as the lowest analyst line in the sand. The two PT raises inside a single week hint at flow warming, but consensus lagging means confirmation still depends on the print. A MATURING turnaround running straight into a binary earnings gate argues for a clean post-print base over chasing the candle — the honest stance here is stand aside into 2026-08-05 and let the report set the level, or size only a small probe.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026, date TBD (est.):** Investor Day to reset long-term financial targets and report strategic-review progress — the structural re-rate catalyst; not yet dated inside this 30-day window.\n- **Ongoing:** further divestiture announcements as the non-core (~7% of revenue) disposal program executes; each removes a drag but shrinks reported revenue.\n\n## Elapsed catalysts\n\n- **2026-08-05 (confirmed):** Q2 2026 earnings, before market open, 9:00 a.m. ET call. The binary. Watch DSA bookings / net book-to-bill, whether Q1's proposal strength converted, the pace of the 120–150 bps margin expansion, and any FY organic-revenue guide revision. *(passed 4d ago)*\n\n## What Would Change Our Mind\n- A weekly close below $140 loses the 2026 post-activist recovery base and the lowest analyst floor — turnaround structure broken, stand aside for a fresh setup.\n- On 2026-08-05: an organic-revenue guide cut, DSA book-to-bill under 1.0, or proposals rolling over invalidates the inflection thesis regardless of where price trades that day.\n- Biotech funding re-freezing (XBI rolling over) removes the demand-recovery leg the bull case leans on.\n- Upside confirmation, not invalidation: a weekly close reclaiming ~$180 on a Q2 that shows DSA bookings inflecting and margins beating would mark the turnaround converting and open the re-rate leg toward the $210–$260 targets.\n\n## Correlation Notes\n- Moves with the CRO / pharma-services complex — IQV, ICLR, MEDP, WST, RGEN, BIO — where DSA demand is a derivative of biotech venture funding and large-pharma R&D budgets.\n- High beta to biotech risk appetite (XBI, IBB): XBI strength is a tailwind to proposals and bookings; weakness pressures the small/mid-biotech cohort that swings CRL's book.\n- Rate-sensitive through the funding channel — easier policy fuels small/mid-biotech spend, which is upstream of preclinical demand.\n- An idiosyncratic activist overlay (Elliott) can decouple CRL from peers on strategic-review, divestiture, or Investor Day headlines, so peer-group beta breaks down around company-specific events.\n\n## Notes\nThis is a turnaround base with a binary print seven-to-eight trading days out, not the accelerating cluster-confirmed momentum leg this book prizes — conviction on a fresh entry at ~$157 is a probe at best until 2026-08-05 clears.",
  "first_seen": "2026-07-24",
  "last_analyzed": "2026-07-25T07:09:22+00:00",
  "last_synthesized": "2026-07-25",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}